MHRI, collaborating clinical site for the Vitamin D and type 2 diabetes (D2d) trial, enrolled the 1000th randomized participant in the nationwide study.
MedStar has been a recruitment leader and is currently the only site in the D2d study that has reached 90% of its time-adjusted goal. Out of all the sites across the United States, the MedStar site has been the first to reach 60% of it's goal, with a total of 90 participants out of a 150-patient goal. MedStar currently is conducting the study at the Hyattsville University Town Center MHRI offices and at the Good Health Center at MedStar Good Samaritan Hospital.
The D2d study is a large clinical trial taking place in more than 22 cities across the United States and is funded by the National Institutes of Health and the American Diabetes Association. The goal of the D2d study is to determine whether Vitamin D supplementation is safe and effective in delaying the onset of type 2 diabetes in people at risk for the disease and to gain a better understanding of how vitamin D affects glucose metabolism. The D2d study will enroll approximately 2,400 participants who are at risk of developing type 2 diabetes. Participants are randomly assigned to receive either vitamin D or placebo and be followed for up to 4 years for development of diabetes. The D2d study is expected to define the role of vitamin D supplementation in modifying diabetes risk in people at risk for the disease.
Congrats to the D2d team and keep up the great work!